Expertise in
10
conditions

Loic Feuvret

Hospices Civils De Lyon
Bron, FR 
Expertise in
10
conditions
Hospices Civils De Lyon
Bron, FR 

Overview

Loic Feuvret practices in Bron, France. Mr. Feuvret is highly rated in 10 conditions, according to our data. His top areas of expertise are Chordoma, Glioma, Gliomatosis Cerebri, and Brain Tumor.

His clinical research consists of co-authoring 106 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

Hospices Civils de Lyon
Bron, France
Other Locations
Hospices civils de Lyon
Lyon, 69000, France
Pitié Salpétrière
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation
Study Drugs: Olaparib, Temozolomide (TMZ)
Study Phase: Phase 1/Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)
A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Radiation, Drug
Study Drug: Durvalumab
Study Phase: Phase 1/Phase 2
Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial.
Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial.
Enrollment Status: Unknown
Publish Date: June 14, 2024
Intervention Type: Radiation, Drug
Study Drug: AGulX
Study Phase: Phase 2
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Enrollment Status: Completed
Publish Date: April 04, 2022
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study
Enrollment Status: Terminated
Publish Date: February 09, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
View 5 Less Clinical Trials

106 Total Publications

Dynamic susceptibility contrast MRI-derived oxygen metabolism and perfusion metrics for distinguishing radiation necrosis from tumor progression in irradiated brain metastases.
Dynamic susceptibility contrast MRI-derived oxygen metabolism and perfusion metrics for distinguishing radiation necrosis from tumor progression in irradiated brain metastases.
Journal: Diagnostic and interventional imaging
Published: September 10, 2025

Frequently Asked Questions about Loic Feuvret

Is Loic Feuvret a top-rated expert for Chordoma?

MediFind is an objective health platform that identifies experts based on real-world data. Loic Feuvret is classified as an Distinguished expert for Chordoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Loic Feuvret participate in research or clinical trials?

Yes. Loic Feuvret has published 106 articles and abstracts on conditions like Chordoma. You can view a list of Loic Feuvret's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Feuvret's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile